“As India achieved high vaccination rates in 2021 and 2022 and the emergence of new mutant variant strains, demand for previous vaccines has decreased significantly. As a result, we have halted the production and supply of additional Covishield doses since December 2021.” A spokesman for SII said on Wednesday.
“We explained all the side effects on the packaging”
In response to the side effects of the vaccine, the Serum Institute of India said that they have disclosed all rare and very rare side effects on the packaging of the vaccine since 2021. “We fully understand the ongoing concerns and it is very important to emphasize our commitment to the vaccine. Transparency and safety From the outset, we have disclosed all rare and very rare side effects, including Thrombosis with Thrombocytopenia Syndrome, in the packaging insert in 2021.” said.
Concerns about the potential health risks of the vaccine, AstraZeneca He acknowledged in court documents that it was a rare side effect of thrombosis with thrombocytopenia syndrome, or TTS. Thrombosis with thrombocytopenia syndrome (TTS) is a rare but serious condition characterized by blood clot formation combined with low platelet levels. TTS, typically linked to certain COVID-19 vaccines, presents with blood clots and decreased platelet counts in unusual locations, such as the brain or abdomen. Symptoms include severe headaches, abdominal pain and neurological disorders. Immediate medical attention is crucial because TTS can lead to life-threatening complications such as stroke or organ damage. Treatment usually includes hospitalization, blood thinners, and close monitoring.
